Fig. 4

Short and long clemastine treatments differently modulate SOD1, LC3-II, CD68 and NF-kB in SOD1-G93A mice spinal cord at the end stage. a Schematic representation of experimental design. b Equal amounts of the total lumbar spinal cord lysates from vehicle and short clemastine-treated SOD1-G93A mice at the end stage (n = 4/group) are subjected to western blotting with anti-SOD1 under non-reducing conditions (right panel shows the monomer band and left panel shows the high molecular weight bands). Anti-GAPDH is used for protein normalisation. c Equal amounts of total lumbar spinal cord lysates from vehicle and short clemastine-treated SOD1-G93A mice at the end stage (n = 4/group) are subjected to western blotting with anti-LC3-I/II or in d with anti-CD68 or in e with anti-NF-kB. Anti-GAPDH is used for protein normalisation. Data represent mean ± S.E.M. Statistical significance is calculated by student’s t test referred to vehicle SOD1-G93A mice, * p < 0.05. f Schematic representation of experimental design. g Equal amounts of total lumbar spinal cord lysates from vehicle- and long clemastine-treated SOD1-G93A mice at the end stage (n = 4/group) are subjected to western blotting with anti-SOD1 under non-reducing conditions (right panel shows the monomer band and left panel shows the high molecular weight bands). h Equal amounts of total lumbar spinal cord lysates from vehicle- and long clemastine-treated SOD1-G93A mice at the end stage (n = 4/group) are subjected to western blotting with anti-LC3-I/II or in i with anti-CD68 or in j with anti-NF-kB. Anti-GAPDH is used for protein normalisation. Data represent mean ± S.E.M. Statistical significance is calculated by student’s t test referred to vehicle SOD1-G93A mice, * p < 0.05